Dermatology
| Atopic Dermatitis
Dermatology
Atopic Dermatitis
Safety of Baricitinib for the Treatment of Atopic Dermatitis Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of 8 Clinical Trials
book_2
Source:
EADV 2024 - Oral session
calendar_today
Published on Medfyle:
October 2024
import_contacts
4
min
In this medfyle
Baricitinib is approved for atopic dermatitis – in some countries in children as young as 2. New data from the final integrated analysis of 8 clinical trials suggest a reassuring safety profile, with no new signals over exposure up to 4.6 years.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
©2024 Infomedica-Medfyle. All rights reserved.
Source: Safety of Baricitinib for the Treatment of Atopic Dermatitis Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of 8 Clinical Trials. Costanzo A, et al. Presented at EADV 2024; FC07.05; Abstract #5625.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
